nav-left cat-right
cat-right

Cobra, Kahr Extend Fusion Protein Development and ...

Cobra Biologics will carry out cell-line and process development of Israeli firm Kahr Medical’s two lead fusion Signal Converter Protein (SCP) candidates KAHR-101 and KAHR-102, for future preclinical and clinical testing. The fusion proteins are in preclinical development for the treatment of cancer and autoimmune disorders. The new contract extends a prior partnership between the firms through which Cobra generated an...

Boehringer Ingelheim, Polyphor Partner on Macrocyc...

Boehringer Ingelheim and Polyphor inked a research collaboration and license agreement through which the latter will apply its MacroFinder® drug discovery platform to identify and optimize macrocyclic drugs against targets selected by BI. The project will focus on targets such as protein-protein interactions that are intractable to small molecule drug discovery approaches. Under terms of the deal BI will be responsible...

GE Healthcare, BGI Explore Stem Cell Genetics with...

GE Healthcare and China-based sequencing firm BGI signed a multiyear stem cell science collaboration that aims to provide new insights into the genetic variation of ethinically diverse human stem cell lines. The ultimate goal is to enable the development of relevant human stem cell assays for use in drug discovery and toxicity. Two projects will initially be undertaken. In the first BGI will carry out genome sequencing...

Immune Pharmaceuticals, Yeda Partner on Her3 Antib...

Immune Pharmaceuticals established a broad collaboration with the Weizmann Institute of Science’s technology transfer company Yeda, focused on developing antibody therapeutics targeting Her3, an epidermal growth factor family target that is overexpressed in some patients with gastric, head and neck, ovarian, and breast cancer. Through the new collaboration Immune will develop and evaluate a number of anti-Her3 antibody...

FDA Clears Novo Nordisk’s Levemir for Diabetic Chi...

FDA approved Novo Nordisk’s long-acting Levemir® (insulin detemir [rDNA origin] injection) for the treatment of type 1 diabetes in patients aged 2–5 years. The drug is the only basal insulin analog indicated for use in young children, the firm points out. Levemir is now approved for the treatment of type 1 diabetes in patients of all ages from 2 years and for treating type 2 diabetes in adults. In September 2011,...

Firefly Bags $500K from Massachusetts Life Science...

Firefly BioWorks received a $500,000 grant from the Massachusetts Life Science Center to further develop its multiplex platform for biomarker detection. The award was made through the Center’s Small Business Matching Grant program, which is designed to provide additional support to companies that have already received Phase 2 SBIR funding from federal agencies. Firefly says the new funds will facilitate the increase of...
Page 20 of 92« First...10...1819202122...304050...Last »